Table 5.
Existing patented vaccines that have been repurposed to treat COVID-19.
| Sr. No. | Vaccine | Publication | Patent Number | Patent Date | Targeted site | Observation | Reference |
|---|---|---|---|---|---|---|---|
| 1. | Live attenuated corona virus vaccines | United State Patent Application | US20060039926 | Feb 23, 2006 | Orf1a/polyprotein (p59/nsp14/ExoN) | MHV virus showed reduction of replication in mice at 5th day with intracerebral inoculation | (https://docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US20060039926.pdf) |
| 2. | DNA based vaccines | International | WO2005081716 | 9 Sept 2005 | calreticulin−nucleocapsid fusion | Resulted in potent nucleocapsid-specific humoral and T cell-mediated immune responses | (Wu et al., 2005) |
| 3. | Protein-Based Vaccines. | International | WO2010063685 | June 10, 2010 | S-Trimer subunit, ACE2 Receptor |
O/W emulsion helped to treat SARS-CoVs by neutralizing antibody responses in animal models | Baras et al. (2012) |
| 4. | Virus-like Particle Vaccines | International | WO2015042373 | 19 Sept 2014 | S protein | The Sera (SAB-300 or SAB-301) were injected into Ad5-hDPP4 transduced BALB/c mice, which protected mice against MERS-COVs | Smith et al. (2015) |
| 5. | mRNA-Based Vaccines. | International | WO2017070626 | April 27, 2017 | mRNA-1273 | Intradermal administration of a lipid nanoparticle (LNP)-encapsulated mRNA mixture encoding MERS-CoVs S proteins into mice resulted in translation in vivo and induction of humoral immune responses |
Ciaramella and Himansu (2017) |